Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 25, 2017
What is the competitive landscape for VALEANT INTL, and when can generic versions of VALEANT INTL drugs launch?
VALEANT INTL has thirteen approved drugs.| Patents: | 4 |
| Tradenames: | 11 |
| Ingredients: | 7 |
| NDAs: | 13 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
tretinoin | Gel | 0.04% | RETIN-A MICRO | 12/20/2010 |
tretinoin | Gel | 0.1% | RETIN-A MICRO | 7/8/2010 |
diltiazem hydrochloride | Extended-release Tablets | 120 mg, 180 mg, 240 mg, 300 mg and 360 mg | CARDIZEM LA | 8/30/2005 |
diltiazem hydrochloride | Extended-release Tablets | 420 mg | CARDIZEM LA | 4/25/2005 |
bupropion hydrochloride | Extended-release Tablets | 150 mg and 300 mg | WELLBUTRIN XL | 9/21/2004 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5,145,675 | Two step method for preparation of controlled release formulations | ► Subscribe | |||||||||||||
| 6,143,327 | Delayed release coated tablet of bupropion hydrochloride | ► Subscribe | |||||||||||||
| 5,879,716 | Methods and compositions for topical delivery of benzoyl peroxide | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| South Africa | 8806284 | ► Subscribe | |||||||||||||
| South Africa | 8906012 | ► Subscribe | |||||||||||||
| Portugal | 1131057 | ► Subscribe | |||||||||||||
| Australia | 613398 | ► Subscribe | |||||||||||||
| Denmark | 1131057 | ► Subscribe | |||||||||||||
| Austria | 293438 | ► Subscribe | |||||||||||||
| Canada | 2307547 | ► Subscribe | |||||||||||||
| Germany | 60019550 | ► Subscribe | |||||||||||||
| United Kingdom | 9921933 | ► Subscribe | |||||||||||||
| European Patent Office | 0277211 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| /2001 | Austria | ► Subscribe | PRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011 | ||||||||||||
| 1304992/01 | Switzerland | ► Subscribe | PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014 | ||||||||||||
| 2013025 | Lithuania | ► Subscribe | PRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323 | ||||||||||||
| C0038 | France | ► Subscribe | PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026 | ||||||||||||
| 2008000041 | Germany | ► Subscribe | PRODUCT NAME: ADAPALEN IN KOMBINATION MIT BENZOYLPEROXID; NAT. REGISTRATION NO/DATE: 67913.00.00 20080229; FIRST REGISTRATION: DAENEMARK 40440 20071218 | ||||||||||||
| 2013 00053 | Denmark | ► Subscribe | PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322 | ||||||||||||
| 1458369/01 | Switzerland | ► Subscribe | PRODUCT NAME: ADAPALENUM + BENZOYLIS PEROXIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58460 19.05.2009 | ||||||||||||
| 13/044 | Ireland | ► Subscribe | PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322 | ||||||||||||
| C/GB11/054 | United Kingdom | ► Subscribe | PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523 | ||||||||||||
| 01/009 | Ireland | ► Subscribe | PRODUCT NAME: PANRETIN-ALITRETINOIN | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,766 others who get our Drug Patent Expiration Alerts:
